Skip to main content

People in the News: Oct 5, 2011

Premium

Synthetic Genomics Vaccines, which focuses on developing vaccines using sequencing and synthetic genomic technologies, has appointed Sammy Farah as president.

Farah joins the company from Immune Design, where he was chief business officer. Previously, he was at Versant Ventures, where he specialized in biotechnology investing; and at Merck, where he led technology support for multiple commercial vaccines.

He holds an MBA from the Wharton School at University of Pennsylvania, a PhD in biochemical engineering from Stanford University, and a BS in biochemical engineering from MIT.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.